Inflammatory bowel diseases (IBDs) are a group of chronic, debilitating disorders of the gastrointestinal tract with peak onset in adolescence and early adulthood. More than 1.4 million people are affected in the USA alone 1 , with an estimated direct healthcare cost of US$6.3 billion per year. IBD affects millions worldwide, and is rising in prevalence, particularly in paediatric and non-European ancestry populations 2 . IBD has two subtypes, ulcerative colitis and Crohn's disease, which have distinct presentations and treatment courses. So far, 200 genomic loci have been associated with IBD 3,4 , but only a handful have been conclusively ascribed to a specific causal variant with direct insight into the underlying disease biology. This scenario is common to all genetically complex diseases, where the pace of identifying associated loci outstrips that of defining specific molecular mechanisms and extracting biological insight from each association.
article reSearcH genotyped or imputed with certainty. Truly high-resolution mapping data, when combined with increasingly sophisticated and comprehensive public databases annotating the putative regulatory function of DNA variants, are likely to reveal novel insights into disease pathogenesis [7] [8] [9] and the mechanisms of disease-associated variants.
Genetic architecture of associated loci
We genotyped 67,852 individuals of European ancestry, including 33,595 with IBD (18,967 Crohn's disease and 14,628 ulcerative colitis) and 34,257 healthy controls using the Illumina ImmunoChip (Extended Data Table 1 ). This genotyping array was designed to include all known variants from European individuals in the February 2010 release of the 1000 Genomes Project 10, 11 in 187 high-density regions known to be associated with one or more immune-mediated diseases 12 . Because fine-mapping uses subtle differences in strength of association between tightly correlated variants to infer which is most likely to be causal, it is particularly sensitive to data quality. We therefore performed stringent quality control to remove genotyping errors and batch effects (Methods). We imputed into this dataset from the 1000 Genomes Project reference panel 13, 14 to fill in variants missing from the ImmunoChip, or filtered out by our quality control (Extended Data Fig. 2 ). We then evaluated the 97 high-density regions that had previous IBD associations 3 and contained at least one variant showing significant association (Methods) in this dataset. The major histocompatibility complex was excluded from these analyses as fine-mapping has been reported elsewhere 15 .
We applied three complementary Bayesian fine-mapping methods that used different priors and model selection strategies to identify independent association signals within a region, and to assign a posterior probability of causality to each variant (Supplementary Methods and Extended Data Fig. 2 ). For each independent signal detected by each method, we sorted all variants by the posterior probability of association, and added variants to the 'credible set' of associated variants until the sum of their posterior probability exceeded 95%: that is, the credible set contained the minimum list of DNA variants that were > 95% likely to contain the causal variant ( Fig. 1 ). These sets ranged in size from 1 to > 400 variants. We merged these results and subsequently focused only on signals where an overlapping credible set of variants was identified by at least two of the three methods and all variants were either directly genotyped or imputed with INFO score > 0.4 (Methods and Fig. 1 ).
In 3 out of 97 regions, a consistent credible set could not be identified; when multiple independent effects exist in a region of very high linkage disequilibrium, multiple distinct fine-mapping solutions may not be distinguishable (Supplementary Note). Sixty-eight of the remaining 94 regions contained a single association, while 26 harboured 2 or more independent signals, for a total of 139 independent associations defined across the 94 regions ( Fig. 2a ). Only IL23R and NOD2 (both previously established to contain multiple associated protein-coding variants 16 ) contained more than three independent signals. Consistent with previous reports 3 , the vast majority of signals were associated with both Crohn's disease and ulcerative colitis, although many of these had a significantly stronger association with one subtype. For the enrichment analyses below, we compared 79 signals that were more strongly associated with Crohn's disease with 23 signals that were more strongly associated with ulcerative colitis (the remaining 37 were equally associated with both subtypes, Supplementary Table 1 ).
Using a restricted maximum likelihood mixed-model approach 17 , we evaluated the proportion of total variance in disease risk attributed to these 94 regions and how much of that was explained by the 139 specific associations. We estimated that 25% of Crohn's disease risk was explained by the specific associations described here, out of a total of 28% explained by these loci (correspondingly for ulcerative colitis: 17% out of 22%). The single strongest signals in each region contributed 76% of this variance explained and the remaining associations contributed 24% (Extended Data Fig. 3 ), highlighting the importance of secondary and tertiary associations in results from genome-wide association studies (GWAS) 15, 18 .
Associations mapped to a single variant
For 18 signals, the 95% credible set consisted of a single variant ('single variant credible sets'), and for 24 others the credible set consisted of 2-5 variants (Fig. 2b) . The single-variant credible sets included five previously reported coding variants: three in NOD2 (fs1007insC, R702W, G908R), a rare protective allele in IL23R (V362I), and a splice variant in CARD9 (c.IVS11+ 1G> C) 16, 19 . The remaining single-variant credible sets comprised three missense variants (I170V in SMAD3, I923V in IFIH1, and N289S in NOD2), four intronic variants (in IL2RA, article reSearcH LRRK2, NOD2, and RTEL1/TNFRSF6B), and six intergenic variants (located 3.7 kilobases (kb) downstream of GPR35; 3.9 kb upstream of PRDM1; within a EP300 binding site 39.9 kb upstream of IKZF1; 500 base pairs (bp) before the transcription start site of JAK2; 9.4 kb upstream of NKX2-3; and 3.5 kb downstream from HNF4A) ( Table 1) . Of note, while physical proximity did not guarantee functional relevance, the credible set of variants for 30 associated loci now implicated a specific gene either because it resided within 50 kb of only that gene or had a coding variant with > 50% probability-improved from only 3 so refined using an earlier HapMap-based definition. Using the same definitions, the total number of potential candidate genes was reduced from 669 to 233. Examples of IBD candidate genes clearly prioritized in our data are described in the Supplementary Box, and a customizable browser (http://finemapping.broadinstitute.org/) is available to review the detailed fine-mapping results.
Associated protein-coding variants
We first annotated the possible functional consequences of the IBD variants by their effect on the amino-acid sequences of proteins. Thirteen out of 45 variants ( Fig. 2c ) that had > 50% posterior probability were non-synonymous (Table 1) , an 18-fold enrichment (enrichment P = 2 × 10 −13 , Fisher's exact test) relative to randomly drawn variants in our regions ( Fig. 3a) . By contrast, only one variant with > 50% probability was synonymous (enrichment P = 0.42). All common coding variants previously reported to affect IBD risk were included in a 95% credible set, including IL23R (R381Q, V362I, and G149R); CARD9 (c.IVS11+ 1G> C and S12N); NOD2 (S431L, R702W, V793M, N852S, and G908R, fs1007insC); ATG16L1 (T300A); PTPN22 (R620W); and FUT2 (W154X). While this enrichment of coding variation ( Fig. 3a ) provided assurance about the accuracy of our approach, it did not suggest that 30% of all associations were caused by coding variants; rather, it was almost certainly the case that associated coding variants had stronger effect sizes, making them easier to fine-map.
Associated non-coding variants
We next examined conserved nucleotides in high-confidence bindingsite motifs of 84 transcription factor families 20 (Methods). There was a significant positive correlation between transcription-factor motif disruption and IBD association posterior probability (P = 0.006, logistic regression) ( Fig. 3a) , including three variants with > 50% probability article reSearcH (two > 95%). In the RTEL1/TNFRSF6B region, rs6062496 is predicted to disrupt a transcription-factor binding motif site (TFBS) for EBF1, a transcription factor involved in the maintenance of B-cell identity and prevention of alternative fates in committed cells 21 . A low-frequency (3.6%) protective allele at rs74465132 creates a binding site for EP300 less than 40 kilobase pairs (kbp) upstream of IKZF1. The third notable example of TFBS disruption, although not in a single variant credible set, is detailed in the Supplementary Box for the association at SMAD3.
Recent studies have shown that trait-associated variants are enriched for epigenetic marks highlighting cell-type-specific regulatory regions 9, 22, 23 . We compared our credible sets with ChIP-seq peaks (chromatin immunoprecipitation followed by sequencing) corresponding to ChIP with H3K4me1, H3K4me3, and H3K27ac (shown previously 22, 23 to highlight enhancers, promoters, and active regulatory elements, respectively) in 120 adult and fetal tissues, assayed by the Roadmap Epigenomics Mapping Consortium 24 (Fig. 3b ). Using a threshold of P = 1.3 × 10 −4 (0.05 corrected for 360 tests), we observed significant enrichment of H3K4me1 in 6 immune cell types and for H3K27ac in 2 gastrointestinal (gut) samples (sigmoid colon and rectal mucosa) ( Fig. 3b and Supplementary Table 2 ). The subset of signals that were more strongly associated with Crohn's disease overlapped more with immune-cell chromatin peaks, whereas ulcerative colitis signals overlapped more with gut chromatin peaks (Supplementary Table 2 ).
These three chromatin marks were correlated both within tissues (we observed additional signal in other marks in the tissues described above) and across related tissues. We therefore defined a set of 'core immune peaks' for H3K4me1 and 'core gut peaks' for H3K27ac as the set of overlapping peaks in all enriched immune cell and gut tissue types, respectively. These two sets of peaks were independently significant and captured the observed enrichment compared with 'control peaks' made up of the same number of ChIP-seq peaks across our 94 regions in non-immune and non-gut tissues ( Fig. 3c, d ). These two tracks summarized our epigenetic-GWAS overlap signal, and the combined excess over the baseline suggested that a substantial number of regions, particularly those not mapped to coding variants, may ultimately be explained by functional variation in recognizable enhancer/ promoter elements.
Overlap with expression quantitative trait loci
Variants that change enhancer or promoter activity might change gene expression, and baseline expression of many genes has been found to be regulated by genetic variation [25] [26] [27] . Indeed, it has been suggested that these so-called expression quantitative trait loci (eQTLs) underlie a large proportion of GWAS associations 25, 28 . We therefore searched for variants that were both in an IBD-associated credible set with 50 or fewer variants, and the most significantly associated eQTL variant for a gene in a study 29 of peripheral blood mononuclear cells (PBMCs) from 2,752 twins. Sixty-eight of the 76 regions with signals fine-mapped to ≤ 50 variants harboured at least one significant eQTL (affecting a gene within 1 megabase with P < 10 −5 ). Despite this abundance of eQTLs in fine-mapped regions, only 3 credible sets included the most signifi-cantly associated eQTL variants, compared with 3.7 expected by chance (Methods). Data from a more recent study 30 using PBMCs from 8,086 individuals did not yield a substantively different outcome, demonstrating a modest but non-significant enrichment (8 observed overlaps, 4.2 expected by chance, P = 0.06). Using a more lenient definition of overlap, requiring the lead eQTL variant to be in linkage disequilibrium (R 2 > 0.4) with an IBD credible set variant, increased the number of potential overlaps but again these numbers were not greater than chance expectation.
As PBMCs are a heterogeneous collection of immune cell populations, cell-type-specific signals or signals corresponding to genes expressed most prominently in non-immune tissues may be missed. We therefore tested the enrichment of eQTLs that overlapped credible sets in five primary immune cell populations (CD4 + , CD8 + , CD19 + , CD14 + , and CD15 + ), platelets, and three distinct intestinal locations (rectum, colon, and ileum) isolated from 350 healthy individuals (Methods). We observed a significant enrichment of credible single nucleotide polymorphism (SNP)/eQTL overlaps in CD4 + cells and ileum (Extended Data Table 2 ): 3 and 2 credible sets overlapped eQTLs, respectively, compared with 0.4 and 0.3 expected by chance (P = 0.005 and 0.020). An enrichment was also observed for the naive CD14 + cells from another study 31 : 8 overlaps observed compared with 2.7 expected by chance (P = 0.001). We did not observe enrichment of overlaps in stimulated (with interferon or lipopolysaccharide) CD14 + cells from the same source (Extended Data Table 2 ).
We investigated eQTL overlaps more deeply by applying two colocalization approaches (one frequentist, one Bayesian, Methods) to our cell-separated dataset where primary genotype and expression data were available. We confirmed greater than expected overlap with eQTLs in CD4 + and ileum described above ( Fig. 4 and Extended Data Table 2 ). These CD4 + co-localized eQTLs also had stronger overlap with CD4 + ChIP-seq peaks than our other credible sets, further supporting a regulatory causal mechanism. The number of colocalizations in other purified cell types and tissues was largely indistinguishable from what we expected under the null using either method, except for moderate enrichment in rectum (4 observed and 1.4 expected, P = 0.039, Frequentist approach) and colon (3 observed and 0.8 expected, P = 0.04, Bayesian approach). Only two of these colocalizations corresponded to an IBD variant with causal probability > 50% (Table 1 and Extended Data Fig. 4a ).
Discussion
We have performed fine-mapping of 94 previously reported genetic risk loci for IBD. Rigorous quality control followed by an integration of three novel fine-mapping methods generated lists of genetic variants accounting for 139 independent associations across these loci. Our methods are concordant with an existing fine-mapping method 6 (67 of 68 credible sets in single-signal regions overlap, including exact matches for all single variant credible sets), and provide extensions to support the phenotype assignment (Crohn's disease, ulcerative colitis, or IBD) and the conditional estimation of multiple credible sets in **** **** article reSearcH loci with multiple independent signals. The use of multiple methods allowed us to focus our downstream analyses on loci where the choice of fine-mapping method did not substantially alter conclusions about the biology of IBD. Our results improve on previous fine-mapping efforts using a preset linkage disequilibrium threshold 32 (for example, r 2 > 0.6) (Extended Data Fig. 5 ) by formally modelling the posterior probability of association of every variant. Much of this resolution derives from the very large sample size we used, because the number of variants in a credible set decreases with increasing significance (P = 0.0069).
The high-density of genotyping also aids in improved resolution. For instance, the primary association at IL2RA has now been mapped to a single variant associated with Crohn's disease, rs61839660. This variant was not present in the HapMap 3 reference panel and was therefore not reported in earlier studies 3, 33 (nearby tagging variants, rs12722489 and rs12722515, were reported instead). Imputation using the 1000 Genomes Project reference panel and the largest assembled GWAS dataset 3 did not separate rs61839660 from its neighbours (H.H., unpublished observations), owing to the loss of information in imputation using the limited reference. Only direct genotyping, available in the ImmunoChip high-density regions, allowed the conclusive identification of the causal variant.
Accurate fine-mapping should, in many instances, ultimately point to the same variant across diseases in shared loci. Among our single-variant credible sets, we fine-mapped an ulcerative colitis association to a rare missense variant (I923V) in IFIH1, which is also associated with type 1 diabetes 34 with an opposite direction of effect (Supplementary Box). The intronic variant noted above (rs61839660, allele frequency = 9%) in IL2RA was also similarly associated with type 1 diabetes, again with a discordant directional effect 35 (Supplementary Box). Simultaneous high-resolution fine-mapping in multiple diseases should therefore better clarify both shared and distinct biology.
Resolution of fine-mapping can be further improved by leveraging linkage disequilibrium from other ethnicities 36 . However, the sample size from other ethnicities we have collected is small compared with European samples (9,846 across East Asian, South Asian, and Middle Eastern). Limited access to matched imputation reference panels from all cohorts and the fact that the smaller non-European sets are not from populations (for example, African-derived) with narrower linkage disequilibrium also suggest that gains in fine-mapping accuracy would be limited at this time. Ultimately this effort will be aided by more substantial investment in genotyping non-European population samples and by developing and applying more robust trans-ethnic fine-mapping algorithms.
A new release of the 1000 Genomes (phase 3) 37 and the UK10K 38 project have introduced new variants that were not present in the reference panel in our study. Our major findings remain the same using this new reference panel: the 18 single-variant credible sets are not in high linkage disequilibrium (r 2 > 0.95) with any new variants in either new dataset, and the 1,426 variants in IBD associations mapped to ≤ 50 variants are in high linkage disequilibrium with only 47 new variants (3.3% of the total size of these credible sets, Supplementary  Table 1 ). Given that this release represents a near-complete catalogue of variants with minor allele frequency (MAF) > 1% in European populations, we believe our current fine-mapping results are likely to be robust, especially for common variant associations. High-resolution fine-mapping demonstrates that causal variants are significantly enriched for variants that alter protein-coding variants or disrupt transcription-factor binding motifs. Enrichment was also observed in H3K4me1 marks in immune-related cell types and H3K27ac marks in sigmoid colon and rectal mucosal tissues, with Crohn's disease loci demonstrating a stronger immune signature and ulcerative colitis loci more enriched for gut tissues (P values 0.014, 0.0005, and 0.0013 respectively for H3K4me1, H3K27ac, and H3K4me3; χ 2 test). By contrast, overall enrichment of eQTLs is quite modest compared with previous reports and not seen strongly in excess of chance in our well-refined credible sets (≤ 50 variants). This result emphasizes the importance of high-resolution mapping and the careful incorporation of the high background rate of eQTLs. It is worth noting that evaluating the overlap between two distinct mapping results is fundamentally different from comparing genetic mapping results to fixed genomic features, and depends on both mappings being well resolved. Although these data challenge the hypothesis that easily surveyed baseline eQTLs explain a large proportion of non-coding GWAS signals, the modest excesses observed in smaller but cell-specific datasets suggest that much larger tissue-or cell-specific studies (and under the correct stimuli or developmental time points) will resolve the contribution of eQTLs to GWAS hits.
Resolving multiple independent associations may often help target the causal gene more precisely. For example, the SMAD3 locus hosts a non-synonymous variant and a variant disrupting the conserved transcription-factor binding site (also overlapping the H3K27ac marker in gut tissues), unambiguously articulating a role in disease and providing an allelic series for further experimental inquiry. Similarly, the TYK2 locus has been mapped to a non-synonymous variant and a variant disrupting a conserved transcription-factor binding site (http:// finemapping.broadinstitute.org/).
One-hundred and sixteen associations have been fine-mapped to ≤ 50 variants. Among them, 27 associations contain coding variants, 20 contain variants disrupting transcription-factor binding motifs, and 45 are within histone H3K4me1-or H3K27ac-marked DNA regions. The best-resolved associations-45 variants having > 50% posterior probabilities for being causal (Table 1 )-are similarly significantly enriched for variants with known or presumed function from genome annotation. Of these, 13 variants cause non-synonymous change in amino acids, 3 disrupt a conserved transcription-factor binding motif, 10 are within histone H3K4me1-or H3K27ac-marked DNA regions in disease-relevant tissues, and 2 co-localize with a significant cis-eQTL (Extended Data Fig. 4a ). Risk alleles of these variants can be found throughout the allele frequency spectrum, with protein-coding variants having somewhat larger effects and more extreme risk allele frequencies (Extended Data Fig. 6a-c) .
This analysis, however, leaves 21 non-coding variants (Extended Data Fig. 4b ), all of which have > 50% probabilities of being causal (five have > 95%), that are not located within known motifs, annotated elements, or in any experimentally determined ChIP-seq peaks or eQTL credible sets yet discovered. While we have identified a statistically compelling set of genuine associations (often intronic or within 10 kb of strong candidate genes), we can make little inference about function. For example, the intronic single-variant credible set of LRRK2 has no annotation, eQTL, or ChIP-seq peak of note. This emphasizes the incompleteness of our knowledge about the function of non-coding DNA and its role in disease, and calls for comprehensive studies on transcriptomes and epigenomes in a wide range of cell lines and article reSearcH stimulation conditions. That most of the best-refined non-coding associations have no available annotation is perhaps sobering with respect to how well we may currently be able to interpret non-coding variation in medical sequencing efforts. It does suggest, however, that detailed fine-mapping of GWAS signals down to single variants, combined with emerging high-throughput genome-editing methodology, may be among the most effective ways of advancing to a greater understanding of the biology of the non-coding genome.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
article reSearcH

MeTHOdS
The study protocols were approved by the institutional review board at each centre involved with recruitment. Informed consent and permission to share the data were obtained from all subjects, in compliance with the guidelines specified by the recruiting centre's institutional review board.
No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. Genotyping and quality control. We genotyped 35,197 unaffected and 35,346 affected individuals (20, 155 Crohn's disease and 15,191 ulcerative colitis) using the ImmunoChip array. Genotypes were called using optiCall 40 for 192,402 autosomal variants before quality control. We removed variants with missing data rate > 2% across the whole dataset, or > 10% in any one batch, and variants that failed (false discovery rate (FDR) < 10 −5 in either the whole dataset or at least two batches) tests for the following: (1) Hardy-Weinberg equilibrium in controls; (2) differential missingness between cases and controls; (3) different allele frequency across different batches in controls, Crohn's disease, or ulcerative colitis. We also removed non-coding variants that were present in the 1000 Genomes pilot stage but were not in the subsequent phase I integrated variant set (March 2012 release) and had not been in releases 2 or 3 of HapMap, as these mostly represented false positives from the 1000 Genomes pilot, which often genotype poorly. Where a variant failed in exactly one batch, we set all genotypes to missing for that batch (to be reimputed later) and included the site if it passed in the remainder of the batches. We removed individuals that had > 2% missing data, had significantly higher or lower (defined as FDR < 0.01) inbreeding coefficient (F), or were duplicated or related (PI_HAT ≥ 0.4, calculated from the linkage disequilibrium pruned dataset described below), by sequentially removing the individual with the largest number of related samples until no related samples remained. We projected all remaining samples onto principal component axes generated from HapMap 3, and classified their ancestry using a Gaussian mixture model fitted to the European (CEU + TSI), African (YRI + LWK + ASW + MKK), East Asian (CHB + JPT), and South Asian (GIH) HapMap samples (CEU, Utah residents with Northern and Western European ancestry from the CEPH collection; TSI, Toscani in Italia; YRI, Yoruba in Ibadan, Nigeria; LWK, Luhya in Webuye, Kenya; ASW, African ancestry in southwest USA; MKK, Maasai in Kinyawa, Kenya; CHB, Han Chinese in Beijing, China; JPT, Japanese in Tokyo, Japan; GIH, Gujarati Indians in Houston, Texas). We removed all samples that were classified as non-European, or that lay more than 8 standard deviations from the European cluster. After quality control, there were 67,852 European-derived samples with valid diagnoses (healthy control, Crohn's disease, or ulcerative colitis), and 161,681 genotyped variants available for downstream analyses. Linkage disequilibrium pruning and principal component analysis. From the clean dataset we removed variants in long-range linkage disequilibrium 41 or with MAF < 0.05, and then pruned three times using the '-indep' option in PLINK (with window size of 50, step size of 5 and VIF threshold of 1.25). Principal component axes were generated within controls using this linkage disequilibrium pruned dataset (18,123 variants) . The axes were then projected to cases to generate the principal components for all samples. The analysis was performed using our in-house C code (https://github.com/hailianghuang/efficientPCA) and LAPACK package 42 for efficiency. Controlling for population structure, batch effects, and other confounders. We used 2,853 'background SNPs' present on the ImmunoChip but not known to be associated with immune disorders to calculate the genomic inflation factor λ GC. After including the first five principal components calculated above as covariates, λ GC = 1.29, 1.25, and 1.31 for Crohn's disease, ulcerative colitis, and IBD (adding additional principal components did not further reduce λ GC , Extended Data Table 3a ). Because our genotype data were processed in 15 batches with variable ratios of cases to controls, we conducted two analyses to ensure possible batch effects were adequately controlled. First, we split the samples into a 'balanced' cohort with studies having both cases and controls, and an 'imbalanced' cohort with studies having exclusively cases or controls (Extended Data Table 1 ). As λ GC under polygenic inheritance scales with the sample size 43 , we randomly down-sampled the full dataset to match the sample size of the balanced and the imbalanced cohorts, respectively. We tested for association in these subsets of our data (and included batch identifier as a covariate in the balanced cohort), and found the λ GC from the balanced and imbalanced cohorts to be within the 95% confidence interval of size-matched values from our full data, suggesting that batch effects were not systematically inflating our association statistics (Extended Data Table 3b ). We also performed a heterogeneity test for the odds ratio of lead variants in each credible set using the balanced and imbalanced cohorts, and observed no significant heterogeneity after Bonferroni correction (Supplementary Table 3 ).
We next sought to disentangle the contributions of polygenic inheritance and uncorrected population structure in our observed λ GC. Linkage disequilibrium score regression 44 is able to differentiate these two effects, but requires genomewide data, so was not possible in our ImmunoChip dataset. Instead, we compared λ GC and λ 1000 values calculated using the same set of background SNPs from the largest IBD meta-analysis with genome-wide data 45 . For both Crohn's disease and ulcerative colitis, the λ 1000 values in our ImmunoChip study (1.012 and 1.012) were equal to or less than those in the genome-wide study (1.016 and 1.012). Furthermore, linkage disequilibrium score regression on the genome-wide data showed that most inflation was caused by polygenic risk (linkage disequilibrium score intercept = 1.09 for both Crohn's disease and ulcerative colitis, compared with λ GC = 1.23 and 1.29). Together, these results show that our residual inflation is consistent with polygenic signal and modest residual confounding. We tested what effect correcting for the linkage disequilibrium score intercept of 1.09 would have on posterior probabilities and credible sets, and found no major differences compared with uncorrected values. The full comparison of λ values is shown in Extended Data Table 3c . Imputation. Imputation was performed separately in each ImmunoChip autosomal high-density region (185 total) from the 1000 Genomes phase I integrated haplotype reference panel. To prevent the edge effect, we extended each side of the high-density regions by 50 kbp. Two imputations were performed sequentially (Extended Data Fig. 2 ) using software and parameters as described below. The first imputation was performed immediately after the quality control, from which the major results were manually inspected ('Manual cluster plot inspection' section in Methods). The second imputation was performed after removing variants that failed the manual cluster plot inspection. We used SHAPEIT 46, 47 (versions: first imputation, v2.r644; second imputation, v2.r769) to pre-phase the genotypes, followed by IMPUTE2 13, 14 Fig. 6d-f) , with similar success rates both for coding and for non-coding variants, making it unlikely that missing variants substantially affected our fine-mapping conclusions. Manual cluster plot inspection. Variants that had posterior probability greater than 50% or in credible sets mapped to ≤ 10 variants were manually inspected using Evoker version 2.2 (ref. 48) . Each variant was inspected by three independent reviewers (ten reviewers participated) and scored as pass, fail, or maybe. Reviewers were blinded to the posterior probability of these variants. We removed variants that received one or more fails, or received fewer than two passes. Two hundred and twenty out of 276 inspected variants passed this inspection, and 53 out of 56 failed variants were restored by imputation. There was no difference in MAF between the failed and the passed variants (P = 0.66). A further cluster plot inspection flagged two additional failed variants after removing the failed variants from the first inspection and re-doing the imputation and analysis. Dramatic clustering errors accounted for 27 out of 58 flagged variants, which were eliminated from final credible sets. The remaining 31 had only minor issues, and the imputed data for these remained in our final credible sets, with marginally smaller posteriors (mean of the difference 9.8%, P = 0.06, paired t-test). Establishing a P value threshold. We used a multiple-testing-corrected P value threshold for associations of 1.35 × 10 −6 , which was established by permutation. We generated 200 permuted datasets by randomly shuffling phenotypes across samples and performed association analyses for each permutation across all variants in high-density regions that overlapped IBD-associated loci 3 . We stored (1) all the point-wise P values (α S ), as well as (2) the 'best' P values (α B ) of each of the 200 permuted datasets. We then computed the empirical, experiment-wide P value (α M ) (corrected for multiple testing) for each of the tests as its rank/200 with respect to the 200 α B . We then estimated the number of independent tests performed in the studied regions, n, as the slope of the regression of log(1 − α M ) on log(1 − α S ), knowing that α M = 1 − | (1 − α S ) n , yielding a value of 37,056. The P value threshold was determined as 0.05/n ≈ 1.35 × 10 −6 . Detecting and fine-mapping association signals. We used three fine-mapping methods (Supplementary Methods) to detect independent signals and create credible sets across 97 ImmunoChip autosomal high-density regions that contained at least one variant with P < 1.35 × 10 −6 . Our process for merging the results of the three methods is described below and illustrated in Fig. 1a. 1. We merged signals from different methods if their credible sets overlapped. To ensure a conservative credible set, this new merged credible set included all variants from all merged signals (the union of constituent credible sets). We assigned each variant in the merged credible sets a posterior probability equal to the average of article reSearcH the probabilities from the methods that reported this signal. To filter out technical artefacts, we required genotyped variants in small credible sets to pass manual cluster plot inspection (see above) and all imputed variants to have INFO > 0.4. For signals reported by only one or two methods that contained only imputed variants (that is, no directly genotyped variants), we additionally required at least one variant with INFO > 0.8 and MAF > 0.01.
2. We next assigned each signal to a provisional combination of lead variant and phenotype (Crohn's disease, ulcerative colitis, or IBD) that maximized the marginal likelihood of equation (8) in Supplementary Methods. 3. At loci with more than one signal, we built a multivariate model with all signals reported by all three methods, and tested all possible combinations of adding signals reported by one or two methods, as long as they still had P < 1.35 × 10 −6 when jointly fitted in the multi-signal model. We selected the combination with the highest joint marginal likelihood (equation (8) in Supplementary Methods) . Phenotype assignment of signals. The provisional phenotype assignment, performed during the signal merging described above, was merely a point estimate and did not capture the uncertainty associated with the phenotypic assignment. We therefore recomputed the assignment of each signal as Crohn's-diseasespecific, ulcerative-colitis-specific, or shared using the Bayesian multinomial model from fine-mapping method 2, empirical covariance prior with Laplace approximation 49 , as it was designed to assess evidence of sharing in the presence of potentially correlated effect sizes. For the lead variant for each credible set, we calculated the marginal likelihoods as in equation (13) from Supplementary Methods, restricting either β UC = 0 (for the Crohn's-disease-only model) or β CD = 0 (for the ulcerative-colitis-only model), as well as using the unconstrained prior (for the associated-to-both model). We then calculated the log(Bayes factor) in favour of sharing; that is, the log of the ratio of marginal likelihoods between the associated-to-both model and the best of the single-phenotype associated models. These sharing log(Bayes factors) are given in Supplementary Table 1 (column 'sharingBF'), and are a probabilistic assessment of phenotype assignment: for instance, the log(Bayes factor) of 97.4 for the primary signal at IL23R suggests a very high certainty that this signal is shared across both Crohn's disease and ulcerative colitis, whereas the log(Bayes factor) of 0.4 for the primary signal at FUT2 is more ambiguous. In addition to providing the log(Bayes factor) itself, we also applied a log(Bayes factor) cut-off of 10 to select variants with strong evidence of being shared across phenotypes. Final filters. These procedures generated some signals where all three methods largely agreed, and some where they differed. While the signals where the methods disagree are of interest for methods development, here we chose to focus on the most concordant signals, as they are most straightforward to interpret biologically. We therefore discarded all signals found by only one method (which completely removed one locus), and two loci where the ratio of marginal likelihoods (equation (8) in Supplementary Methods) for the best model and the second-best model was < 10 (Supplementary Notes). After these filters (Extended Data Fig. 7) , we considered 139 signals from 94 regions (containing a total of 181,232 variants) to be confidently fine-mapped, and took them forward for subsequent analysis. Estimating the variance explained by the fine-mapping. We used a mixed-model framework to estimate the total risk variance attributable to the IBD risk loci, and to the signals identified in the fine-mapping. We used the GCTA software package 50 to compute a gametic relationship matrix (G-matrix) using genotype dosage information for the genotyped variants in the high-density regions (which we will call G HD ). We then fitted a variety of variance component models by restricted maximum likelihood analysis using an underlying liability threshold model implemented with the DMU package 51 . The first model was a standard heritability mixed-model that included fixed effects for five principal components (to correct for stratification) and a random effect summarizing the contribution of all variants in the fine-mapping regions, such that the liabilities across all individuals were distributed according to where λ 1 is thus the variance explained by all variants in fine-mapping regions, which we estimated. We then fitted a model that included an additional random effect for the contribution of the lead variants that had been specifically identified (with G-matrix G Signals ), such that the liability was distributed as The variance explained by the signals under consideration was then given by the reduction in the variance explained by all variants in the fine-mapping regions between the two models (λ 1 − ′ λ 1 ). We used this approach to estimate what fraction of this variance was accounted for by (1) the single strongest signals in each region (as would be typically done before fine-mapping), or (2) all signals identified in fine-mapping. We used Cox and Snell's method 52 to estimate the variance explained across individual signals (Extended Data Fig. 3b ) for computational efficiency. Overlap between transcription-factor binding motifs and causal variants. For each motif in the ENCODE transcription factor ChIP-seq data (http://compbio. mit.edu/encode-motifs/, accessed November 2014) 20 , we calculated the overall information content as the sum of information content for each position 53 , and only considered motifs with overall information content ≥ 14 bits (equivalent to seven perfectly conserved positions). For every variant in a high-density region, we determined whether it created or disrupted a motif at a high-information site (information content ≥ 1.8).
Overlap between epigenetic signatures and causal variants. For each combination of 120 tissues and 3 histone marks (H3K4me1, H3K4me3, and H3K27ac) from the Roadmap Epigenome Project, we calculated an overlap score, equal to the sum of fine-mapping posterior probabilities for all variants in peaks of that histone mark in that tissue. We generated a null distribution of this score for each tissue/ mark by shifting chromatin marks randomly (between 0 bp and 44.53 megabase pairs, the length of all high-density regions) and circularly (peaks at the end of the region shifted to the beginning of the region) over the high-density regions while keeping the same inter-peak distances. To summarize these correlated results across many cell and tissue types, we defined a set of 'core' H3K4me1 immune and H3K27ac gut peaks as sets of overlapping peaks in cells that showed the strongest enrichment. Intersects were made using bedtools version 2.24.0 default settings 54 . We selected six immune cell types for H3K4me1 and three gut cell types for H3K27ac (Supplementary Table 2 ). We also chose controls (Supplementary Table 2 ) from non-immune and non-gut cell types with similar density of peaks in the fine-mapped regions compared with immune/gut cell types to confirm the tissue-specificity of the overlap. We used the phenotype assignments (described above) in dissecting the enrichment for the Crohn's disease and ulcerative colitis signals. Sixty-five Crohn's disease and 21 ulcerative colitis signals that were mapped to ≤ 50 variants were used in this analysis. Published eQTL summary statistics. We used eQTL summary statistics from three published studies. Table 2 in ref. 31 , comprising 432 European individuals, measured in a naive state and after stimulation with interferon-γ or lipopolysaccharide (for 2 or 24 h), reporting loci with MAF > 4% and FDR < 0.05. Imputation was performed using the 1000 Genomes reference panel 10 . Processing and quality control of new eQTL ULg dataset. A detailed description of the ULg dataset is in preparation (Y.M. et al., in preparation). Briefly, we collected venous blood and intestinal biopsies at three locations (ileum, transverse colon, and rectum) from 350 healthy individuals of European descent, average age 54 (range 17-87), 56% female. SNPs were genotyped on Illumina Human OmniExpress version 1.0 arrays interrogating 730,525 variants, and SNPs and individuals were subjected to standard quality control procedures using call rate, Hardy-Weinberg equilibrium, MAF ≥ 0.05, and consistency between declared and genotype-based sex as criteria. We further imputed genotypes at ∼ 7 million variants on the entire cohort using the Impute2 software package 13 and the 1,000 Genomes Project as reference population (phase 3 integrated variant set, released 12 October 2014) 11, 14 . From the blood, we purified CD4 + , CD8 + , CD19 + , CD14 + , and CD15 + cells by positive selection, and platelets (CD45 − ) by negative selection. RNA from all leucocyte samples and intestinal biopsies was hybridized on Illumina Human HT-12 arrays version 4. After standard quality control, raw fluorescent intensities were variance stabilized 56 and quantile normalized 57 using the lumi R package 58 , and were corrected for sex, age, smoking status, number of probes with expression level significantly above background as fixed effects and array number (sentrix id) as the random effect. For each probe with measurable expression (detection P value < 0.05 in > 25% of samples), we tested for cis-eQTLs at all variants within a 500 kbp window. The nominal P value of the best SNP within a cis-window was Sidak-corrected for the window-specific number of independent tests. The number of independent tests in each window was estimated exactly in the same manner as for the number of independent tests for fine-mapping methods ('Establishing a P value threshold' section in Methods). We estimated false discovery rates (q values) from the resulting P values across all probes using the qvalue R package 59 . Four hundred and eighty cis-eQTL with FDR ≤ 0.10 for which the lead SNPs (that is, the SNP yielding the best P value for the cis-eQTL) mapped within the 97 high-density regions (94 fine-mapped plus 3 unresolved) were retained for further analyses.
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Naive co-localization using lead SNPs. We calculated the number of IBD credible sets containing a lead eQTL variant in a particular tissue ('observed'). This number was then compared with the background number of overlaps ('expected'):
where N i is the total number of variants in region i in 1,000 genomes with an allele frequency greater than a certain threshold (equal to the threshold used for the original eQTL study), C i is the number of these variants that lie in IBD credible sets, and S is a set of regions that have at least one significant eQTL. We simulated 1,000 trials per region with binomial probability equal to the regional background overlap rate:
Empirical P values were estimated by comparing the observed number of overlaps with the simulated number of the overlaps. More specifically, the P value was defined as the proportion of trails having equal or more overlaps in the simulations than the observed. Frequentist co-localization using conditional P values. We next used conditional association to test for evidence of co-localization, as described in ref. 25 . This method compares the P value of association for the lead SNP of an eQTL before and after conditioning on the SNP with the highest posterior in the credible set, and measures the drop in −log(P). An empirical P value for this drop is then calculated by comparing it to the drop for all variants in the high-density region. Because this method requires full genotypes, we could only apply it to the ULg dataset (MAF > 5%). An empirical P value ≤ 0.05 was considered as evidence that the corresponding credible set was co-localized with the corresponding cis-eQTL. To evaluate whether our fine-mapping associations co-localized with cis-eQTL more often than expected by chance, we counted the number of credible sets affecting at least one cis-eQTL with P ≤ 0.05, and compared how often this number was matched or exceeded by 1,000 sets of variants that were randomly selected yet distributed among the loci in accordance with the real credible sets. The number of variants per set was same as the number of credible sets in this eQTL analysis (MAF matched, size ≤ 50), shown in Extended Data Table 2 . Bayesian co-localization using Bayes factors. Finally, we used the Bayesian colocalization methodology described in ref. 60 , modified to use the credible sets and posteriors generated by our fine-mapping methods (similarly only applicable to the ULg full genotype data). The method takes as input a pair of IBD and eQTL signals, with corresponding credible sets S IBD and S eQTL , and posteriors for each variant p i IBD and p i eQTL (with = ∀ ∉ p i S 0 i X X ). Credible sets and posteriors were generated for eQTL signals using the Bayesian quantitative association mode in SNPTest (with default parameters), with credible sets in regions with multiple independent signals generated conditional on all other signals. Our method calculated a Bayes factor (BF) summarizing the evidence in favour of a co-localized model (that is, a single underlying causal variant between the IBD and eQTL signals) compared with a non-co-localized model (where different causal variants were driving the two signals), given by the ratio of marginal likelihoods In both cases, N is the total number of variants in the region. We only counted towards N variants having r 2 > 0.2 with either the lead eQTL variant or the lead IBD variant.
To measure enrichment in co-localization BFs compared with the null, we performed a permutation analysis. In this analysis, we randomly reassigned eQTL signals to new fine-mapping regions to generate a set of simulated null datasets. This was done using the following scheme on variants and credible sets with the same MAF cut-off as the eQTL dataset (ULg, MAF > 5%). (1) Estimate the standardized effect size β g for each eQTL signal g, equal to standard deviation increase in gene expression for each dose of the minor allele. (2) Randomly reassign each eQTL signal to a new fine-mapping region, and then select a new causal variant with a MAF within 1% of the lead variant from the real signal. If multiple such variants exist, select one at random. If no such variants exist, pick the variant with the closest MAF. (3) Generate new simulated gene expression signals for each individual from Normal(β g x j , 1 − β g 2 2f(1 − f)), where x j is the individual's minor allele dosage at the new causal variant and f is the MAF. (4) Carry out fine-mapping and calculate co-localization Bayes factors for each pair of (real) IBD signals and (simulated) eQTL signals. (5) Repeat stages (2)-(4) 1,000 times for each tissue type. We can use these permuted Bayes factors to calculate P values for each IBD credible set, given by the proportion of time the permuted Bayes factors were as large or greater than the one observed in the real dataset. To generate a high-quality set of co-localized eQTL and IBD signals, we take all IBD signals that have the co-localization BF > 2, P < 0.01, and r 2 (with the eQTL variant) > 0.8. Code availability. Computer code used in this study is provided in the 'Software availability' sections in the Supplementary Methods. Data availability. The data that support the findings of this study are available from the International Inflammatory Bowel Disease Genetics Consortium but restrictions apply to the availability of these data, which were used under licence for the current study, and so are not publicly available. Data are, however, available from the corresponding authors upon reasonable request and with the permission of the International Inflammatory Bowel Disease Genetics Consortium. Comparison of credible set sizes for primary signals using each of our fine-mapping methods (methods 1, 2, and 3), the combined approach (as adopted in final results) and the approach described in ref. 6 (y axis) and the r 2 > 0.6 cut-off (x axis). Fine-mapping maps most signals to smaller numbers of variants. The trend line (blue) and the confidence interval (grey) were calculated using the geom_smooth function in the R ggplot2 package using the linear model.
Extended Data Figure 7 | Merging and adjudicating signals across methods. The number of signals for each method is shown in the brackets, and for each method a black bar indicates a signal with P < 1.35 × 10 −6 , and a grey bar a signal that does not reach that threshold. The coloured bar shows the final status of each signal after merging and model selection (Methods). Label 'low INFO' corresponds to INFO < 0.8 (the threshold used for signals reported by one or two methods), and 'rare and imputed' to MAF < 0.01 and no genotyped variants in the credible set, regardless of INFO (Methods). article reSearcH extended data Table 2 | Co-localization with eQTL
The number of IBD credible sets that co-localize with eQTLs using the naive, frequentist, and Bayesian approaches. Significant observations are set in bold type. 'Number of credible sets' reports the number of credible sets that have MAF above the cut-off. IFN, interferon-γ; LPS, lipopolysaccharide.
